


# DNDi PAEDIATRIC HIV STAKEHOLDERS' MEETING

Wednesday, 3 October 2018

Time: 09:00-16:30

Venue: Speke Resort, Munyonyo, Kampala, Uganda



**Background:** Given the need to address critical gaps in the treatment of infants and young children living with HIV, DNDi has been working since 2013 to develop child-adapted formulations of antiretroviral therapy (ART) through several partnerships. DNDi is currently working with Cipla Ltd. to develop a “4-in-1” fixed-dose formulation, made up of abacavir, lamivudine, lopinavir and ritonavir (ABC/3TC/LPV/r), that is taste-masked, heat-stable, easy to use, and child friendly. It is in its final stages of development and would represent a major improvement of the paediatric HIV drug armamentarium.

While the 4-in-1 development is ongoing, DNDi, with academic partners in Kenya, Uganda, and Tanzania, tested the already US FDA-approved LPV/r pellets in a large-scale implementation study, the LIVING study. Interim results of this study have been presented in international conferences showing good outcomes in children.

This meeting will bring together key partners of DNDi to discuss vital issues concerning access to ART adapted to the needs of infants and young children living with HIV, their families, and their caregivers.

## Preliminary Agenda

*Event Moderator: Olawale Salami*

*DNDi rapporteurs: Part 1: Moses Waveru, Part 2: Seth Oluoch Odhiambo, Part 3: Flavia Kyomuhendo*

08.30-09.00	Arrival (coffee)
09.00-09.20	Opening speeches and meeting objectives > François Bompert (DNDi) > Sara Padidar (Unitaid)
<b>Part 1- New treatments for children living with HIV: DNDi's journey so far</b> <i>Chair: François Bompert (DNDi)</i>	
09.20-09.45	Update on DNDi's paediatric HIV programme > Isabelle Andrieux-Meyer (DNDi)
09.45-10.15	Pharmaceutical development of LPV/r-based formulations to meet the needs of infants and children: what lessons have we learned? > Jean-René Kiechel (DNDi)
10.15-10.30	Questions and discussion
10.30-11.00	Coffee break

## Part 2- Panel discussion: Front-line experience from clinical study and programmatic implementation

Chair: Prof Adeodata Kekitiinwa (Baylor Uganda)

Co-chair: Dr Mastidia Rutaihwa (MoH, Tanzania)

11.00-11.30	LIVING study experience from the investigators: what have we learned in Kenya, Uganda and Tanzania > Speakers: Dr Caren Mburu (Kenyatta Hospital, Nairobi, Kenya), Dr Kathy Kyakwera (MSF/ Epicentre, Uganda), Dr Nzovu Ulenga (MDH, Tanzania)
11.30-11.40	Questions and discussion
11.40-12.10	Uptake of LPV/r-based formulations (syrup and pellets) in children: experience from Kenya and Uganda > Speakers: Dr Laura Oyiengo (MoH Kenya), Dr Cordelia Katureebe (MoH Uganda)
12.10-12.30	Questions and discussion
12.30-13.30	Lunch

## Part 3: Looking forward – Access

Chair: Olawale Salami (DNDi)

13.30-13.50	An update on the pharmacokinetic and safety study of the 4-in-1 formulation > Dr Victor Musiime (Makerere University/JCRC, Uganda)
13.50-14.10	New WHO treatment guidelines for children living with HIV and implications for programme implementation > Prof Elizabeth Obimbo (Kenyatta Hospital, Nairobi, Kenya)
14.10-14.30	The role of civil society in spearheading advocacy for better treatment options in children living with HIV > Proscovia Namakula (Global Coalition of Women Against AIDS)
14.30-15.10	Questions and discussion
15.10-15.30	Coffee break
15.30-16.00	What are the key considerations in ensuring access to child-adapted ARV formulations in 2019 and beyond? - Open discussion
16.00-16.30	Meeting recap and final remarks
16.30	END OF MEETING
16.30-18:00	COCKTAIL / RECEPTION